MedTrace Logo

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

NCT02880007 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-03-10

No results posted yet for this study

Summary

This prospective phase II trial study aims to optimize the increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy in treating patients with locally advanced cervical cancer.

Conditions

  • Cervical Adenocarcinoma
  • Stage IB Cervical Cancer
  • Stage II Cervical Cancer
  • Stage III Cervical Cancer

Interventions

RADIATION

External Beam Radiation Therapy

45 Gy pelvis / 25 fr

RADIATION

PDR Brachytherapy

1 puls/hour ; 12 Gy / day

DRUG

Cisplatin

increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy

Sponsors & Collaborators

  • Institut de Cancérologie de Lorraine

    lead OTHER

Principal Investigators

  • PEIFFERT Didier · Institut de Cancérologie de Lorraine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-06
Primary Completion
2014-02-10
Completion
2019-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880007 on ClinicalTrials.gov